In this episode, Iris Bincovich, CEO of Innocan Pharma shares Innocan’s collaboration with Tel Aviv University to develop a novel, revolutionary approach to treat COVID-19 by using CBD loaded Exosomes. In addition to treating COVID-19, the new drug will target additional central nervous system indications. The goal is to be ready in 2021 to conduct a licensing agreement with a large pharma company.

Additionally, Iris shared that Innocan will be launching their new line of CBD topicals, produced in Portugal and the US, during Q2 of this year, including a line of “relief and go” pain-relief topicals as well as a line of cosmetic products.

Interested in being a distributor? Contact: [email protected]